| Literature DB >> 35446890 |
Ali Umar1, Muhammad Saleem Khan1, Sheikh Arslan Sehgal2, Kamran Jafar1, Shabbir Ahmad1, Ahmad Waheed1, Muhammad Waseem Aslam1, Muhammad Wajid1, Tanzil Ur Rehman1, Tehmina Khan1, Allah Ditta1, Hasnain Akmal1, Muhammad Ashfaq1, Tariq Javed1, Rida Tahir1.
Abstract
Sleep is one of the most important functions of the life. The disturbance in sleep or quality of sleep leads to several dysfunctions of the human body. This study aimed to investigate the prevalence of sleep disorders, their possible risk factors and their association with other health problems. The data was collected from the educational community of the Pakistani population. The Insomnia Severity Index (ISI) was used to evaluate the insomnia and the sleep apnea was evaluated through a simple questionnaire method. The blood samples were collected to perform significant blood tests for clinical investigations. Current research revealed that the individuals in the educational community had poor sleep quality. A total of 1998 individuals from the educational community were surveyed, 1584 (79.28%) of whom had a sleep disorders, including insomnia (45.20%) and sleep apnea (34.08%). The measured onset of age for males and females was 30.35 years and 31.07 years respectively. The Clinical investigations showed that the sleep had significant impact on the hematology of the patients. Higher levels of serum uric acid and blood sugar were recorded with a sleep disorder. The individuals of the educational community were using the sleeping pills. The other associated diseases were mild tension, headaches, migraines, depression, diabetes, obesity, and myopia. The use of beverage, bad mood, medical condition, mental stress, disturbed circadian rhythms, workload and extra use of smartphone were major risk factors of sleep disorders. It was concluded that the insomnia was more prevalent than the sleep apnea. Furthermore, life changes events were directly linked with disturbance of sleep. Tension, depression, headaches, and migraine were more associated with sleep disorders than all other health issues.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35446890 PMCID: PMC9022811 DOI: 10.1371/journal.pone.0266739
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1Flow sheet of research methodology.
Demographic characteristics of the respondent.
| Participant Characteristics | Respondents | |
|---|---|---|
| N | % | |
|
| ||
|
| 990 | 49.55 |
|
| 1008 | 50.45 |
|
| ||
|
| 621 | 31.08 |
|
| 714 | 35.74 |
|
| 396 | 19.82 |
|
| 267 | 13.36 |
|
| ||
|
| 1437 | 71.92 |
|
| 561 | 28.08 |
|
| ||
|
| 975 | 48.8 |
|
| 1023 | 51.2 |
Sleep durations of respondents.
| Participant Characteristics | Shorter Sleepers (N = 837) | Normative Sleepers (N = 876) | Longer Sleepers (N = 285) | X2 | P-Value | |||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |||
|
| ||||||||
|
| 444 | 53.05 | 411 | 46.92 | 135 | 47.37 | 7.06 | 0.03 |
|
| 393 | 46.95 | 465 | 53.08 | 150 | 52.63 | ||
|
| ||||||||
|
| 282 | 33.69 | 267 | 30.48 | 72 | 25.26 | 23.12 | <0.001 |
|
| 258 | 30.82 | 351 | 40.07 | 105 | 36.84 | ||
|
| 183 | 21.86 | 150 | 17.12 | 63 | 22.11 | ||
|
| 114 | 13.62 | 108 | 12.33 | 45 | 15.79 | ||
|
| ||||||||
|
| 417 | 49.82 | 441 | 50.34 | 165 | 57.89 | 6.01 | 0.05 |
|
| 420 | 50.18 | 435 | 49.66 | 120 | 42.11 | ||
|
| ||||||||
|
| 576 | 68.82 | 633 | 72.26 | 228 | 80 | 13.25 | <0.001 |
|
| 261 | 31.18 | 243 | 27.74 | 57 | 20 | ||
** = Highly significant (P<0.01) NS = Non-significant (P>0.05)
* = Significant (P<0.05), X2 = Chi-square.
Prevalence of sleep disorders.
| Participant Characteristics | Sleep apnea 34.08% | Insomnia 45.20% | Over all prevalence 79.28% | X2 | P-Value | |||
|---|---|---|---|---|---|---|---|---|
| N | % | n | % | n | % | |||
|
| ||||||||
|
| 330 | 33.33 | 432 | 43.64 | 762 | 38.14 | 0.059 | 0.808 |
|
| 351 | 34.82 | 471 | 46.73 | 822 | 41.14 | ||
|
| ||||||||
|
| 195 | 31.4 | 285 | 45.89 | 480 | 24.02 | 5.608 | 0.469 |
|
| 222 | 31.09 | 288 | 40.34 | 510 | 25.53 | ||
|
| 132 | 33.33 | 186 | 46.97 | 318 | 15.92 | ||
|
| 132 | 49.44 | 144 | 53.93 | 276 | 13.81 | ||
|
| ||||||||
|
| 360 | 25.05 | 450 | 31.32 | 810 | 40.54 | 1.99 | 0.369 |
|
| 321 | 57.22 | 453 | 80.75 | 774 | 38.74 | ||
|
| ||||||||
|
| 486 | 49.85 | 612 | 62.77 | 1098 | 54.95 | 3.33 | 0.189 |
|
| 195 | 19.06 | 291 | 28.45 | 486 | 24.32 | ||
** = Highly significant (P<0.01) NS = Non-significant (P>0.05)
* = Significant (P<0.05), X2 = Chi-square.
Symptoms and prevalence of insomnia.
| Participant Characteristics | Insomnia sub threshold 1 symptom (n = 552) | Mild insomnia 2 symptoms (n = 543) | Severe insomnia 3 symptoms (n = 903) | X2 | P- Value | |||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | n | % | |||
|
| ||||||||
|
| 279 | 28.18 | 279 | 28.18 | 432 | 43.64 | 3.109 | 0.211 |
|
| 273 | 27.08 | 264 | 26.19 | 471 | 46.73 | ||
|
| ||||||||
|
| 174 | 28.02 | 162 | 26.09 | 285 | 45.89 | 32.992 | 0.001 |
|
| 240 | 33.61 | 186 | 26.05 | 288 | 40.34 | ||
|
| 84 | 21.21 | 126 | 31.82 | 186 | 46.97 | ||
|
| 54 | 20.22 | 69 | 25.84 | 144 | 53.93 | ||
|
| ||||||||
|
| 276 | 26.98 | 297 | 29.03 | 450 | 43.99 | 3.649 | 0.161 |
|
| 276 | 28.31 | 246 | 25.23 | 453 | 46.46 | ||
|
| ||||||||
|
| 405 | 28.18 | 420 | 29.23 | 612 | 42.59 | 16.183 | 0.001 |
|
| 147 | 27.37 | 123 | 22.91 | 291 | 54.19 | ||
** = Highly significant (P<0.01) NS = Non-significant (P>0.05)
* = Significant (P<0.05), X2 = Chi-square.
Symptoms and prevalence of sleep apnea in studied population.
| Participant Characteristics | 1 symptom (n = 693) | 2 symptoms (n = 624) | 3 symptoms (n = 681) | X2 | P-value | |||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | n | % | |||
|
| ||||||||
|
| 354 | 51.08 | 306 | 49.04 | 330 | 48.46 | 1.041 | 0.594 |
|
| 339 | 48.92 | 318 | 50.96 | 351 | 51.54 | ||
|
| ||||||||
|
| 219 | 35.27 | 207 | 33.33 | 195 | 31.40 | 40.15 | 0.001 |
|
| 267 | 37.39 | 225 | 31.51 | 222 | 31.09 | ||
|
| 150 | 37.88 | 114 | 28.79 | 132 | 33.33 | ||
|
| 57 | 21.35 | 78 | 29.21 | 132 | 49.44 | ||
|
| ||||||||
|
| 336 | 32.84 | 327 | 31.96 | 360 | 35.19 | 3.161 | 0.206 |
|
| 357 | 36.62 | 297 | 30.46 | 321 | 32.92 | ||
|
| ||||||||
|
| 468 | 32.57 | 483 | 33.61 | 486 | 33.82 | 16.002 | 0.001 |
|
| 225 | 40.11 | 141 | 25.13 | 195 | 40.11 | ||
** = Highly significant (P<0.01) NS = Non-significant (P>0.05)
* = Significant (P<0.05), X2 = Chi-square.
Respondents suffering from tension.
| Participant Characteristics | Participants suffering from Tension (N = 1998) | |||||
|---|---|---|---|---|---|---|
| Yes (n = 729) | % | No (n = 1269) | % | X2 | P-Value | |
| Gender | ||||||
|
| 345 | 34.85 | 645 | 65.15 | 2.272 | 0.132 |
|
| 384 | 38.10 | 624 | 61.90 | ||
|
| ||||||
|
| 210 | 33.82 | 411 | 66.18 | 45.963 | 0.001 |
|
| 237 | 33.19 | 477 | 66.81 | ||
|
| 135 | 34.09 | 261 | 65.91 | ||
|
| 147 | 55.06 | 120 | 44.94 | ||
|
| ||||||
|
| 333 | 32.55 | 690 | 67.45 | 14.009 | 0.001 |
|
| 396 | 40.62 | 579 | 59.38 | ||
|
| ||||||
|
| 513 | 35.70 | 924 | 64.30 | 1.368 | 0.242 |
|
| 216 | 38.50 | 345 | 61.50 | ||
** = Highly significant (P<0.01) NS = Non-significant (P>0.05)
* = Significant (P<0.05), X2 = Chi-square.
Participants using sleeping pills.
| Participant Characteristics | Yes (n = 168) | Rarely (n = 207) | No (n = 1623) | X2 | P- Value | |||
|---|---|---|---|---|---|---|---|---|
| N | % | n | % | n | % | |||
|
| ||||||||
|
| 81 | 8.18 | 87 | 8.79 | 822 | 83.03 | 5.585 | 0.061 |
|
| 87 | 8.63 | 120 | 11.90 | 801 | 79.46 | ||
|
| ||||||||
|
| 45 | 7.25 | 57 | 9.18 | 519 | 83.57 | 47.298 | 0.001 |
|
| 69 | 9.66 | 75 | 10.50 | 570 | 79.83 | ||
|
| 27 | 6.82 | 21 | 5.30 | 348 | 87.88 | ||
|
| 27 | 10.11 | 54 | 20.22 | 186 | 69.66 | ||
|
| ||||||||
|
| 78 | 7.62 | 126 | 12.32 | 819 | 80.06 | 9.631 | 0.008 |
|
| 90 | 9.23 | 81 | 8.31 | 804 | 82.46 | ||
|
| ||||||||
|
| 120 | 8.35 | 144 | 10.02 | 1173 | 81.63 | 0.689 | 0.712 |
|
| 48 | 8.56 | 63 | 11.23 | 450 | 80.21 | ||
** = Highly significant (P<0.01) NS = Non-significant (P>0.05)
* = Significant (P<0.05), X2chi-square.
Clinical assessment with respect to sleep disorder.
| Variable | Reference Value | Mean | SD | Range (Minimum-Maximum) |
|---|---|---|---|---|
|
| 3.5–10 | 11.58 | 2.7 | 7.58–15.4 |
|
| 3.8–5.8 | 4.86 | 0.58 | 3.8–5.45 |
|
| 12.0–17.0 | 13 | 2.87 | 7.1–17 |
|
| 34–47 | 38.37 | 8.26 | 22.2–47.5 |
|
| 75–95 | 78.92 | 11.77 | 58.1–92.4 |
|
| 24–32 | 26.44 | 4.65 | 8.6–32 |
|
| 11.0–14.0 | 14.93 | 3.61 | 11.2–18.4 |
|
| 31–35 | 32.43 | 5.02 | 22.5–36.7 |
|
| 150–450 | 291 | 122.27 | 109–509 |
|
| 1.8–7.5 | 6.4 | 1.41 | 4.8–9.9 |
|
| 1.5–4 | 3.71 | 1.01 | 2.3–5.43 |
|
| 0.2–0.8 | 4.83 | 2.29 | 0.94–8 |
|
| 0–0.6 | 1.75 | 1.58 | 0.05–5.9 |
|
| 70–130 | 122.5 | 32.32 | 76–173 |
|
| 2.4–6 | 5.73 | 1.6 | 2.9–8 |
|
| 60–100 | 102.70 | 11.63 | 87–122 |
Associated risk factors of sleep disorder (N = 1998).
| Risk factor | N | Percentage |
|---|---|---|
|
| 1095 | 54.80 |
|
| 1146 | 57.36 |
|
| 645 | 32.28 |
|
| 729 | 36.49 |
|
| 588 | 29.43 |
|
| 1400 | 70.07 |
Fig 2Associated diseases with sleep disorders.
Fig 3Age of onset of sleep disorders.